CD8A and breast cancer: In BC, IL10 predominantly performs three biological activities that contribute to tumor-inhibiting action: (1) promoting CD8+ T-cell activation and proliferation and (2) inhibiting both T-cell-stimulated tumor-killing immunity by suppressing antigen presentation by APCs and (3) tumor-promoting inflammation [83,84,85].